ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on ArriVent BioPharma, Inc.. The associated price target remains the same with $42.00.

Robert Burns has given his Buy rating due to a combination of factors related to ArriVent’s lead asset, firmonertinib, and its late-stage clinical strategy. He highlights the upcoming Phase 3 FURVENT readout in first-line EGFR Exon 20 insertion-positive NSCLC as a major value driver, noting that the trial is designed to show a meaningful progression-free survival advantage over standard platinum-based chemotherapy plus pemetrexed. He also underscores management’s view that a chemo- and amivantamab-free monotherapy regimen could be more tolerable than competing combination approaches, while still leaving room for future combination strategies with firmonertinib. Supporting this, Burns points to the strong response rates seen with firmonertinib 240 mg in the Phase 1b FAVOUR study across both treatment-naïve and previously treated Exon 20 insertion patients, which compare favorably to existing options.
In addition, Burns emphasizes the potential for firmonertinib in EGFR PACC-mutant NSCLC through the pivotal ALPACCA trial, which is structured to allow for an interim assessment of overall response rate that could enable accelerated approval. The trial is backed by compelling Phase 1b FURTHER data, including prolonged median progression-free survival, durable responses, and robust intracranial activity. He notes that real-world evidence suggests differing efficacy and tolerability profiles between afatinib and osimertinib in PACC mutations, and that the relative performance of firmonertinib against each comparator in ALPACCA will be key. Taken together, the late-stage catalysts, favorable early efficacy and CNS data, and a potentially differentiated safety and convenience profile underpin his conviction that ArriVent shares offer attractive upside at current levels.

In another report released on January 11, LifeSci Capital also maintained a Buy rating on the stock with a $36.00 price target.